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A B S T R A C T   
Barth syndrome (BTHS) is a rare, X-linked cardiomyopathy that is characterized by abnormalities in glucose and 
lipid metabolism, with less known regarding amino acid metabolism. This pilot study characterized whole-body 
arginine kinetics and found lower arginine rate of appearance into plasma (0.69 ± 0.09 vs. 0.88 ± 0.06 μmol/ 
kgFFM/min, p < 0.01) and arginine non-oxidative disposal rate (0.64 ± 0.11 vs. 0.80 ± 0.03 μmol/kgFFM/min, 
p < 0.02) in adolescents and young adults with BTHS compared to Controls. This study provides a foundation for 
more in-depth studies on how arginine and potentially other amino acid abnormalities contribute to the pa-
thology and clinical manifestations of BTHS.   
1.1. Introduction 
Barth syndrome (BTHS) is a rare, X-linked cardioskeletal myopathy 
caused by recessive mutations in the tafazzin (TAZ) gene [1] resulting in 
metabolic disturbances including an increased monolysocardiolipin to 
cardiolipin ratio, 3-methyglutaconic aciduria [2], hypocholesterolemia 
[3]. Although dysregulated cardiac [4] and skeletal muscle [5] glucose 
and fatty acid metabolism and energetics [6] have been reported, much 
less in known about amino acid metabolism in BTHS. 
Low plasma arginine concentration in BTHS [7–9] has received 
considerable clinical attention and a proportion of patients have been 
treated with oral L-arginine and L-citrulline amino acid supplementation 
[10]. However, other features of arginine metabolism, including argi-
nine kinetics, are not known in BTHS. Therefore, the objective of this 
pilot study was to characterize whole-body arginine kinetics in a pilot 
sample of adolescents and young adults with BTHS. 
1.2. Methods 
1.2.1. Participants 
Nine (n = 9) participants: n = 5 individuals with BTHS, and n = 4 
healthy non-affected controls matched for age, height, weight, body- 
mass index (BMI), and activity level participated. All participants were 
considered sedentary defined as participation in routine exercise ≤2×/ 
week. Participants with BTHS were recruited from the Barth Syndrome 
Foundation Registry located at the University of Florida. Control par-
ticipants were recruited from the Volunteers for Health at Washington 
University School of Medicine and the surrounding St. Louis community. 
Studies were approved by the Human Studies Committee at Washington 
University in St. Louis and all participants and parents (of adolescents) 
provided written informed consent. 
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1.2.2. Body composition 
Each participant underwent whole-body dual energy x-ray absorp-
tiometry (DXA) scans (Lunar iDXA; GE Healthcare Lunar, Madison, WI) 
to determine regional and composite fat-free mass (FFM) and fat mass 
(kg) and percentage. 
1.2.3. Arginine kinetics 
The evening prior to the study visit, participants consumed a stan-
dardized meal and ingested a carbohydrate beverage as previously 
described [5]. Participants reported fasted to the Washington University 
Clinical Research Unit the following day at 0700 h. A catheter was 
inserted into an antecubital vein and used to administer stable 
isotopically-labeled tracers. A second catheter was inserted into a hand 
vein on the contralateral arm; the hand was heated (55 ◦C) using a 
thermostatically controlled box to obtain arterialized venous blood 
samples [11]. Following 30-min of rest, a constant intravenous infusion 
of [U-13C6]arginine (Cambridge Isotope Laboratories, Andover, MA; 
0.04 μmol/kg fat-free mass (FFM)/min) was initiated and maintained for 
a 360-min study period [12]. Blood and breath samples were collected in 
vacutainers before starting the tracer infusions to quantify background 
arginine and 13CO2 enrichments, and collected every 30 min during the 
last 120 min of the study to quantify hormone levels, substrate levels, 
and arginine kinetics [13]. Whole-body oxygen consumption (V̇O2) and 
carbon dioxide production (V̇CO2) was measured continuously for 15 
min at 300 min of the study using indirect calorimetry (Parvo Medics, 
Sandy, UT). 
1.3. Sample analyses 
1.3.1. Plasma substrate and hormone concentrations 
Plasma glucose and insulin concentrations were determined as pre-
viously described [5]. Plasma arginine quantification was performed at 
St. Louis Children’s Hospital via tandem mass spectrometric analysis. 
For kinetic analysis, plasma amino acids were converted into their 5- 
dimethylamino-1-naphthalene sulfonamide derivatives, and arginine 
tracer-to-tracee (TTR) ratio was measured by selected reaction moni-
toring on a triple quadrupole mass spectrometer using precursor ion m/z 
408 to product ion 391 for arginine and precursor ion m/z 414 to 
product ion 397 for 13C6-arginine [14]. The chromatographic separation 
was achieved with a SynergiTM Max-RP column (150 × 2 mm, 4 μm; 
Phenomenex, Torrance, CA, USA) with a security guard cartridge system 
(Phenomenex). The isotope analysis was carried out using a TSQ Van-
tage triple quadrupole mass spectrometer (Thermo Fisher Scientific, San 
Jose, CA, USA) equipped with a heated electrospray ionization (HESI) 
source. 
1.3.2. Arginine kinetics 
Plasma arginine rate of appearance (Ra) into plasma was calculated 
by dividing the tracer infusion rate by the average TTR obtained during 
the last 120 min of the study period. Plasma arginine oxidation rate was 
determined by dividing breath 13CO2 production ([13CO2 TTR/6] ×
VCO2 production) by the plasma arginine TTR. Non-oxidative disposal 
rate was determined by subtracting arginine oxidation rate from argi-
nine Ra [13]. Arginine incorporation into glucose was determined by 
measuring 13C-glucose enrichment with gas chromatography- 
combustion-isotope ratio mass spectrometry (Thermo Finnigan Del-
ta+XL GC-C-IRMS) coupled with a 6890 GC (Agilent Technologies). 
1.4. Statistical analysis 
All data were evaluated for normality. Independent t-tests or Mann- 
Whitney U test were used to compare differences between groups 
depending on normality. A two-tailed P-value of ≤0.05 was considered 
statistically significant. 
1.5. Results 
1.5.1. Demographics and body composition 
Participants did not differ in age, height, or total body mass but in-
dividuals with BTHS had significantly lower FFM (kg) than Control 
(Table 1). 
1.5.2. Arginine kinetics and amino acid concentration 
Arginine Ra into plasma and arginine non-oxidative disposal rate 
were lower in BTHS vs. Control. Arginine oxidation rate, metabolic 
clearance rate, and arginine metabolite incorporation into glucose were 
not different between groups. 
1.6. Discussion 
The primary finding of our study was that arginine rate of appear-
ance was lower in adolescents and young adults with BTHS, even when 
normalized for lower fat-free mass and is the first evidence of dysregu-
lated arginine kinetics in BTHS. These data suggest that reduced argi-
nine rate of appearance might contribute to lower plasma arginine 
concentration in BTHS however; these data need to be confirmed in a 
larger, more expansive study. In addition, non-oxidative disposal was 
also lower in those with BTHS compared to healthy controls. Lastly, we 
also found that arginine incorporation into glucose was not different 
between those with and without BTHS. We had previously shown that 
cardiac and skeletal muscle glucose utilization is upregulated in BTHS 
[4,5,7]. On the basis of these observations, we hypothesized that a 
greater amount of arginine might be incorporated into glucose (i.e. 
higher gluconeogenesis) in those with BTHS; however, this does not 
appear to be the case in this small sample. A limitation of this study was 
the small sample size thus larger and more in-depth studies of arginine 
metabolism in BTHS would help clarify the role of arginine kinetics in 
low plasma arginine concentration and potentially other clinical mani-
festations of BTHS. 
In conclusion, arginine kinetics were dysregulated in a small pilot 
sample of adolescents and young adults with BTHS. This study provides 
Table 1 
Demographics and arginine kinetics.   
BTHS Control P value 
Demographics  
Age 25.0 ± 7.5 29.8 ± 6.0 0.34 
Height (cm) 179.6 ± 6.7 182.9 ± 1.8 0.38 
BMI 19.8 ± 5.4 24.1 ± 2.7 0.41 
Total mass (kg) 61.5 ± 19.9 76.6 ± 9.9 0.21 
FFM (kg) 42.1 ± 9.8 59.7 ± 4.9 0.01 
FFM (%) 71 ± 10 78 ± 4 0.19 
Fat mass (kg) 19.4 ± 11.1 16.9 ± 5.2 0.69 
Fat mass (%) 29 ± 10 22 ± 4 0.19 
Insulin (μU/mL) 11.5 ± 3.9 3.8 ± 2.7 <0.01 
Glucose (mg/dL) 90.8 ± 9.7 87.6 ± 2.5 0.47 
Arginine kinetics  
Arginine concentration (μmol/L) 78.4 ± 20.2 94.5 ± 28.8 0.19 
Arg Ra (μmol/kgFFM/min) 0.69 ± 0.09 0.88 ± 0.06 <0.01 
Arg Ox (μmol/kgFFM/min) 0.05 ± 0.04 0.08 ± 0.05 0.19 
Arg Non-Ox Disp (μmol/kgFFM/ 
min) 
0.64 ± 0.11 0.80 ± 0.03 <0.03 





Arg/Glu enrichment (%) 0.06 ± 0.01 0.05 ± 0.03 0.85 
FFM: fat free mass, Ra: rate of appearance into plasma, Ox: arginine oxidation 
rate, MCR: metabolic clearance rate, Arg: arginine, Glu: glucose. 
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a foundation for more in-depth studies on how arginine and potentially 
other amino acid abnormalities contribute to the pathology and clinical 
manifestations of BTHS. 
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